Article
[Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Verhandlungen der Deutschen Gesellschaft fur Pathologie - 1 Jan 2007
Wardelmann E, Merkelbach-Bruse S, Büttner R, Schildhaus H U
Abstract excerpt
AIMS: Receptor tyrosine kinases have been shown to be a challenging target for the treatment of hematologic diseases and solid tumors. One very effective tyrosine kinase inhibitor is imatinib mesylate inhibiting the KIT receptor tyrosine kinase in gastrointestinal stromal tumors (GISTs) which often carry activating mutations in the KIT gene. Our own observations show that the location of the underlying mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.